Fresenius buys Dabur's Indian oncology business
Fresenius is to acquire India's Dabur Pharma for $219 million giving it access to a portfolio of cancer treatment drugs and a supply of raw materials.
IndiaÆs Dabur Group has sold its 73.3% controlling interest in Dabur Pharma to Fresenius Kabi for Ç139 million $219 million.
Dabur Pharma is the residual pharmaceuticals business of Dabur Group. The largest business of the group, which is owned by the Delhi-based Burman family, is Dabur India. Dabur India has been operating since 1884 and is today a $250 million company focused on healthcare, personal care and food products. Its brands are especially well respected in the ayurvedic category,...
To continue reading, please login or register for free